Detalhe da pesquisa
1.
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
Cancer;
130(3): 400-409, 2024 02 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37864520
2.
Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.
Cancer;
130(7): 1061-1071, 2024 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38009662
3.
Obesity is associated with improved progression-free survival in Microsatellite-Instability-High endometrial cancer treated with pembrolizumab.
Gynecol Oncol;
180: 139-145, 2024 Jan.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38091773
4.
Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.
Cancer;
129(11): 1672-1680, 2023 06 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36930815
5.
Phase II Trial of MEDI0457 and Durvalumab for Patients With Recurrent/Metastatic Human Papillomavirus-Associated Cancers.
Oncologist;
28(7): 618-623, 2023 07 05.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37104874
6.
Selinexor in combination with weekly paclitaxel in patients with metastatic solid tumors: Results of an open label, single-center, multi-arm phase 1b study with expansion phase in ovarian cancer.
Gynecol Oncol;
168: 76-82, 2023 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36423446
7.
Hormone receptor status and the role of oophorectomy in uterine leiomyosarcoma.
Gynecol Oncol;
167(3): 490-495, 2022 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36270831
8.
Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis.
Gynecol Oncol;
165(3): 664-670, 2022 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35400527
9.
Contemporary primary treatment of women with stage II-IV low-grade serous ovarian/peritoneal cancer (LGSOC): Determinants of relapse and disease-free survival.
Gynecol Oncol;
167(2): 139-145, 2022 11.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36137845
10.
Gynecologic tract melanoma in the contemporary therapeutic era: High rates of local and distant disease progression.
Gynecol Oncol;
167(3): 483-489, 2022 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36229264
11.
A Not So Perfect Score: Factors Associated with the Rate of Straight Line Scoring in Oncology Training Programs.
J Cancer Educ;
37(3): 615-620, 2022 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32839894
12.
The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial.
Invest New Drugs;
39(3): 829-835, 2021 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33415580
13.
Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer.
Gynecol Oncol;
162(1): 24-31, 2021 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33958211
14.
Factors associated with response to neoadjuvant chemotherapy in advanced stage ovarian cancer.
Gynecol Oncol;
162(1): 65-71, 2021 07.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33838925
15.
Pulmonary resection for tissue harvest in adoptive tumor-infiltrating lymphocyte therapy: Safety and feasibility.
J Surg Oncol;
124(4): 699-703, 2021 Sep.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34057733
16.
Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer.
Int J Gynecol Cancer;
31(1): 92-97, 2021 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-33154095
17.
Immuno-Oncology for Gynecologic Malignancies.
Adv Exp Med Biol;
1342: 193-232, 2021.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34972966
18.
Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract.
Gynecol Oncol;
158(3): 570-575, 2020 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32534809
19.
Phase II evaluation of nivolumab in the treatment of persistent or recurrent cervical cancer (NCT02257528/NRG-GY002).
Gynecol Oncol;
157(1): 161-166, 2020 04.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31924334
20.
Immuno-oncology for Gynecologic Malignancies.
Adv Exp Med Biol;
1244: 149-182, 2020.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32301014